公开(公告)号：US11208633B2

公开(公告)日：2021-12-28

申请号：US16704744

申请日：2019-12-05

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US10946086B2

公开(公告)日：2021-03-16

申请号：US16245378

申请日：2019-01-11

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G. K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  A61K39/39 ,  A61K39/40 ,  A61K39/00 ,  C07K16/12 ,  C07K16/44 ,  A61K47/10 ,  A61K47/26

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20150291940A1

公开(公告)日：2015-10-15

申请号：US14436875

申请日：2013-10-07

Applicant: PFIZER INC.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

Abstract translation: 一方面，本发明涉及包含突变型艰难梭菌毒素A和/或突变型艰难梭菌毒素B的免疫原性组合物。突变毒素可以包括具有至少一个突变的葡糖基转移酶结构域和至少具有至少一个突变的半胱氨酸蛋白酶结构域 一个突变，相对于相应的野生型艰难梭菌毒素。 突变毒素可以包括至少一个化学交联的氨基酸。 另一方面，本发明涉及用于培养艰难梭菌和产生艰难梭菌毒素的方法和组合物。

公开(公告)号：US20250002875A1

公开(公告)日：2025-01-02

申请号：US18593348

申请日：2024-03-01

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US20190112584A1

公开(公告)日：2019-04-18

申请号：US16104938

申请日：2018-08-19

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US09777076B2

公开(公告)日：2017-10-03

申请号：US14412646

申请日：2013-07-03

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Srinivas Kodali ,  Evguenii Vinogradov

IPC: A61K31/715 ,  A61K47/48 ,  C08B37/00 ,  C08H1/00

CPC classification number: C08B37/006 ,  A61K31/715 ,  A61K47/64 ,  A61K47/646 ,  C08H1/00

Abstract: The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from Enterococcus faecium. In a further aspect, the invention relates to a saccharide having a repeating unit of -6-β-D-Fruf-2, wherein Fru is a fructose moiety, wherein the saccharide is from Enterococcus faecium. In another aspect, the invention relates to an isolated antibody or fragment thereof that specifically binds to a saccharide described herein and uses thereof.

公开(公告)号：US11952597B2

公开(公告)日：2024-04-09

申请号：US16922952

申请日：2020-07-07

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

CPC classification number: C12N9/1051 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US20210024903A1

公开(公告)日：2021-01-28

申请号：US16922952

申请日：2020-07-07

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US10226525B2

公开(公告)日：2019-03-12

申请号：US15144884

申请日：2016-05-03

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G. K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/00 ,  C07K16/12 ,  C07K16/44 ,  A61K39/40 ,  A61K39/09 ,  A61K39/39 ,  A61K47/10 ,  A61K47/26

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20160002361A1

公开(公告)日：2016-01-07

申请号：US14412646

申请日：2013-07-03

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Srinivas Kodali ,  Evguenii Vinogradov

IPC: C08B37/00 ,  A61K31/715 ,  A61K47/48

CPC classification number: C08B37/006 ,  A61K31/715 ,  A61K47/64 ,  A61K47/646 ,  C08H1/00

Abstract: The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from Enterococcus faecium. In a further aspect, the invention relates to a saccharide having a repeating unit of -6-β-D-Fruf-2, wherein Fru is a fructose moiety, wherein the saccharide is from Enterococcus faecium. In another aspect, the invention relates to an isolated antibody or fragment thereof that specifically binds to a saccharide described herein and uses thereof.

Abstract translation: 本发明涉及新型糖类及其用途。 一方面，本发明涉及具有军团氨基酸部分，N-乙酰半乳糖胺部分，半乳糖部分和葡萄糖部分的糖。 另一方面，本发明涉及具有丙二醛酸部分，岩藻糖部分和葡萄糖部分的糖。 另一方面，本发明涉及具有甘油磷酸酯部分和葡萄糖部分的重复单元的糖类，其中所述糖类来自屎肠球菌。 另一方面，本发明涉及一种具有重量单位为6-bgr-D-Fruf-2的糖类，其中Fru是果糖部分，其中糖类来自屎肠球菌。 另一方面，本发明涉及与本文所述的糖类及其用途特异性结合的分离的抗体或其片段。